Leading U.S. medical professionals advising the government have decided to recommend a booster dose of Pfizer’s Covid-19 vaccine to everyone over the age of 16 because of concerns about potential side effects in the younger age group. I opposed it.
A day after data presentation and debate, a panel of vaccinologists, infectious disease researchers, and epidemiologists voted 16-2 against the bill, but the door to agree on the third shot. I left it open. senior citizen..
Paul Offit of the Philadelphia Children’s Hospital said, “We would probably support the three-dose recommendation for people over the age of 60 or 65, but as written for people over the age of 16. It’s really hard to support. “
The decision expressed criticism of President Joe Biden’s administration, which announced plans to begin rolling out booster shots this month before consulting with scientific institutions.
However, many experts say they are needed amid concerns about global injustice and the potential increased risk of rare side effects, including myocarditis (heart inflammation), especially in young men. I have expressed my reservation.
The Food and Drug Administration (FDA) has made a cautious tone in a document released prior to the Friday meeting when an independent panel was convened.
“Overall, the data show that the Covid-19 vaccine currently licensed or licensed in the United States still provides protection against severe Covid-19 disease and death in the United States,” the FDA said in its briefing. Stated in the document.
Peter Marks, senior FDA scientist at the conference, told participants to “focus on science, not operational issues related to booster campaigns or issues related to global vaccine fairness.” I asked.
After the vote, the panel chair said he would create a new question about whether to approve the vaccine among older groups, for example 65 years or older, whose risk and benefit profiles differ significantly.
Then, on September 22-23, we will move to another committee convened by the US Centers for Disease Control and Prevention (CDC) to decide how to proceed.
Continued effectiveness for hospitalization
At the meeting, Pfizer officials cited a study showing that the immune system was weakened against infection months after the first two doses.
Donna Voice, Pfizer’s Senior Vice President of Global Regulation, said:
However, an increasing number of US studies, including the dataset presented by Pfizer himself at the Friday meeting, have shown that two doses continue to provide high protection against serious consequences, which is a lot. Emphasized by the panelists.
Pfizer also presented data showing that boosters increased antibody levels against delta mutants.
Sharon Alroy Preis, an employee of the Israeli Ministry of Health, presented data from her country that ran a booster campaign after experiencing the delta wave and approved the booster for everyone over the age of 12.
“Management amplifier The dose helped Israel weaken the serious case in the fourth wave, “she said.
As part of that, the FDA believes in its briefing document that not all studies are reliable and that US-based studies “may best represent the effectiveness of vaccines in the US population.” Said that.
US medical professionals voting for Pfizer COVID boosters
© 2021 AFP
Quote: US Government Advisors are 16 years of age or older (September 18, 2021) obtained from https://medicalxpress.com/news/2021-09-govt-vote-pfizer-covid-boosters on September 18, 2021. ) Voted against the Pfizer Covid Booster. html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
US govt advisers vote no to Pfizer Covid boosters for ages 16 and up Source link US govt advisers vote no to Pfizer Covid boosters for ages 16 and up
The post US govt advisers vote no to Pfizer Covid boosters for ages 16 and up appeared first on California News Times.